| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1996;27:668-671.)
© 1996 American Heart Association, Inc.
Articles |
From the Medical Service, Department of Veterans Affairs Medical Center, and Department of Physiology, University of Mississippi Medical Center, Jackson, Miss.
Correspondence to A.R. Patel, MD, Medical Service, Department of Veterans Affairs Medical Center, 1500 E Woodrow Wilson Dr, Jackson, MS 39216.
| Abstract |
|---|
|
|
|---|
Key Words: Na+,K+-transporting ATPase homeostasis natriuresis bufanolides
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Forty minutes after completion of surgery, RPP was adjusted to approximately 100 mm Hg by tightening of the aortic clamp above the renal arteries. After a 15-minute equilibration period, urine was collected over a 40-minute experimental period. A blood sample (400 µL) was obtained at the midpoint of the collection period. The plasma was removed and the red cells were suspended in a small amount (400 µL) of 154 mmol/L sodium chloride and returned to the animal. In the control group, the aortic clamp was then released, allowing RPP to return to its baseline values (approximately 125 mm Hg). After a 15-minute equilibration period, urine and blood samples were collected over a 40-minute experimental period as described above. RPP was then increased approximately 25 mm Hg above baseline value by tightening of the aortic clamp below the renal arteries and the ligatures on the celiac and superior mesenteric arteries. Urine and blood were again collected as previously described. The clamps were then released and a final ambient blood pressure was determined. The bufalin-infused group was studied in a similar manner at RPPs of 100, 125, 150, and 180 mm Hg. To ensure that the order of collection did not influence the findings, the order of pressure adjustment was varied in some rats from each group.
After the final blood pressure determination, the animal was exsanguinated while still under anesthesia and the kidneys were removed and weighed.
In two additional sets of rats (n=6 per group), RBF was determined with 131I-hippuran (Isotex Inc) with the use of an identical protocol.
Analytical Techniques
Urine flow rate was determined by
change in weight of preweighed
vials. Plasma and urine samples were evaluated for
[125I]iothalamate and 131I-hippuran activity
on a gamma counter (Packard Instrument Inc). Sodium concentration in
urine and plasma samples was determined with the use of a flame
photometer (model 943, Instrumentation Laboratories).
Analysis of Data
Determination of the activity of
[125I]iothalamate, activity of 131I-hippuran,
sodium concentration in plasma and urine, and urine flow rate permitted
calculation of GFR, RBF, and urinary sodium excretion rate according to
standard expressions.16 RBF was calculated from hippuran
clearance, renal hippuran extraction, and hematocrit as described
previously. Urinary excretion data, RBF, and GFR were all expressed per
gram kidney weight.
To examine the effects of bufalin on the autoregulation of GFR and RBF, the autoregulatory index was calculated according to the method of Sample and de Wardener as previously described from our laboratory.16 17
All values are expressed as mean±SE. Statistical significance between values at different RPPs within a single group of animals was determined with the use of ANOVA for repeated measures followed by Tukey test. Statistical significance between groups was determined with the use of the unpaired Student's t test.
| Results |
|---|
|
|
|---|
Renal function at each group's ambient RPP is shown in the
Table
. There were no differences in GFR, urinary flow
rate, and absolute or fractional urinary sodium excretion between
vehicle- and bufalin-treated rats at their ambient RPPs. RBF was
lower (P<.05) in bufalin-treated rats than control rats
when measured at their ambient RPPs.
|
In the control group, GFR was unaltered during changes in RPP
(Fig 1
). GFR decreased with decreasing RPP in the
bufalin group. The GFR fell to 411±109 µL/min per gram kidney
weight
at 100 mm Hg, a value significantly lower than that observed at 125 mm
Hg (Fig 1
). The absolute differences in GFR between the control
and
bufalin groups reached statistical significance only at an RPP of 100
mm Hg. The GFR autoregulatory index between 150 and 100 mm Hg was
significantly greater (P<.05) in bufalin-treated rats
than in control rats (Fig 2
).
|
|
RBF was unaltered during changes in RPP in control rats (Fig
3
). RBF decreased during decreases in RPP between 180
and 150 mm Hg and between 125 and 100 mm Hg in bufalin-treated
rats. RBF was significantly less in bufalin-treated rats than
control rats at 150 and 100 mm Hg. The RBF autoregulatory index between
150 and 100 mm Hg was less (P<.05) in control rats than
bufalin-treated rats.
|
Absolute urinary sodium excretion also increased with increasing RPP in
both groups (Fig 4
). Absolute urinary sodium excretion
was significantly lower (P<.05) in bufalin-treated rats
at an RPP of 125 and 150 mm Hg than control rats. The slope of the line
relating sodium excretion to RPP over the range of pressures for which
comparable data were available (100 to 150 mm Hg) was significantly
greater (P<.05) in the control group (252.8±56.6
µmol/min per millimeter of mercury) compared with the bufalin group
(72.4±21.8 µmol/min per millimeter of mercury). Fractional urinary
sodium excretion demonstrated a similar pattern (data not shown).
|
Urinary flow rate increased as RPP increased in both groups (data not shown). Urinary flow rate was significantly less (P<.05) in the bufalin-treated group compared with the control group at 100, 125, and 150 mm Hg. The slope of the line relating urinary flow rate to RPP over the range of pressures for which comparable data were available (100 to 150 mm Hg) was significantly greater (P<.05) in the control group (1.26±0.27 µL/min per millimeter of mercury) than in the bufalin-treated group (0.35±0.09 µL/min per millimeter of mercury).
| Discussion |
|---|
|
|
|---|
Bufalin was chosen to inhibit Na+,K+-ATPase in the present study because Na+,K+-ATPase inhibition with this compound induces both acute and chronic hypertension in the rat.3 4 In the rat, in vitro studies have demonstrated that bufalin is a more potent inhibitor of myocardial Na+,K+-ATPase than ouabain.18 19 This may in part account for the ability of bufalin to induce both acute and chronic increases in blood pressure whereas ouabain induces increases in blood pressure only when given chronically. Although studies with ouabain-induced hypertension may be more relevant for examining the potential role of Na+,K+-ATPase inhibition in the pathogenesis of hypertension in humans,5 the renal effects of chronic Na+,K+-ATPase inhibition are difficult to separate from effects due to structural renal damage induced by exposure of the kidney to prolonged elevations in RPP. Thus, acute studies are more appropriate to determine the potential role of the kidney in hypertension induced by inhibition of Na+,K+-ATPase.
The present study clearly demonstrates that acute inhibition of Na+,K+-ATPase has adverse effects on renal function, which could contribute to an increase in arterial pressure. Bufalin not only impaired autoregulation of both RBF and GFR but also decreased RBF and GFR. The autoregulatory index for GFR and RBF increased from slightly >0 in normal animals to >1 after inhibition of Na+,K+-ATPase with bufalin (P<.05). When autoregulatory indexes are expressed in this manner, a value of 0 reflects perfect autoregulation whereas a level >1 reflects the absence of autoregulation in a system in which vascular resistance is fixed. These observations in vivo are consistent with in vitro findings that inhibition of Na+,K+-ATPase in isolated vessels or vascular rings produces dose-dependent vasoconstriction and inhibition of the responses to vasodilators.2 20 21 Our studies are also in agreement with previous work by Tamaki and associates22 demonstrating that acute intrarenal ouabain administration impairs autoregulation of RBF and GFR in the dog.
Acute inhibition of Na+,K+-ATPase also blunted the relationship between RPP and urinary fluid or sodium excretion. Alterations in pressure natriuresis or diuresis could be due to increases in preglomerular resistance either because of intrinsic changes in afferent arteriolar tone or because of resetting of the macula densa feedback mechanism.14 15 Alternatively, Na+,K+-ATPase inhibition could reduce the glomerular capillary filtration coefficient (Kf) or have direct effects on increasing tubular reabsorption. Which of these factors accounts for the alterations in pressure natriuresis remains to be determined.
Whether the alterations in RBF and GFR and the changes in the pressure-natriuresis relationship are due to direct effects of Na+,K+-ATPase inhibition on the renal vasculature and tubular transport or result from responses to systemic Na+,K+-ATPase inhibition remains to be determined. Inhibition of Na+,K+-ATPase with ouabain has been proposed to increase blood pressure through excitation of the sympathetic nervous system, whereas bufalin has been postulated to potentiate vasoconstrictor responses to norepinephrine.2 10 23 On the other hand, inhibition of Na+,K+-ATPase with bufalin has been shown to cause concentration-dependent contraction of human arterial rings and produces renal vasoconstriction after direct infusion into the renal artery.10 21 Thus, the alterations in renal function observed after Na+,K+-ATPase inhibition in the present study could occur through either direct or indirect mechanisms.
Bufalin-induced hypertension has been examined previously by others. Pamnani and associates3 reported that bolus intravenous administration of bufalin induced dose-dependent increases in blood pressure, heart rate, and cardiac contractility. Eliades and associates2 confirmed these observations during intravenous bufalin infusion and further demonstrated that bufalin infused into the canine forelimb induced vasoconstriction, potentiated the vasoconstrictor responses to norepinephrine, and reduced the vasodilator response to potassium chloride. None of the previous studies rigorously examined renal function. RBF reportedly has been reduced during Na+,K+-ATPase inhibition with bufalin in the dog, which is in agreement with our present observations in the rat. Urinary sodium and water excretion have been noted to be unchanged from control values during bufalin infusion in most previous studies.2 3 10 18 This lack of an increase in urinary fluid or sodium excretion despite a large increase in MAP is suggestive evidence that normal pressure-natriuretic and diuretic responses were impaired during Na+,K+-ATPase inhibition with bufalin in these reports. Thus, the findings from these previous studies would be consistent with our observations as well.
In summary, the present study demonstrates that inhibition of Na+,K+-ATPase with bufalin results in significant increases in renal vascular resistance and impairment of the regulation of RBF and GFR and markedly reduces pressure natriuresis and diuresis in the rat. These events may contribute to the sustained increases in blood pressure observed during chronic Na+,K+-ATPase inhibition in the rat.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
2.
Eliades D, Swindall B, Johnston J, Pamnani M, Haddy
F. Hemodynamic effects of bufalin in the
anesthetized dog. Hypertension. 1989;13:690-695.
3.
Pamnani MB, Chen S, Bryant HJ, Schoolry JF Jr, Eliades
DC, Yuan CM, Haddy FJ. Effects of three sodium-potassium
adenosine triphosphatase inhibitors.
Hypertension. 1991;18:316-324.
4. Pamnani MB, Chen S, Yuan CM, Haddy FJ. Chronic blood pressure effects of bufalin, a sodium-potassium ATPase inhibitor, in rats. Hypertension. 1994;23(suppl I):I-106-I-109.
5.
Hamlyn JM, Blaustein MP, Bova S, Ducharme DW, Harris
DW, Mandel F, Mathews WR, Ludens JH. Identification and
characterization of a ouabain-like compound from human
plasma. Proc Natl Acad Sci U S A.. 1991;88:6259-6263.
6. Hamlyn JM, Ringel R, Schaeffer J, Levinson PD, Hamilton BP, Kowarski AA, Blaustein MD. A circulating inhibitor of (Na++K+) ATPase associated with essential hypertension. Nature. 1982;300:650-652. [Medline] [Order article via Infotrieve]
7. DeWardener HE, MacGregor GA. Dahl's hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure: its possible role in essential hypertension. Kidney Int. 1980;18:1-9. [Medline] [Order article via Infotrieve]
8. Woolfson RG, Graves J, LaBella FS, Templeton JF, Poston L. Effect of bufalin and pregnanes on vasoreactivity of human resistance arteries. Biochem Biophys Res Commun. 1992;186:1-7. [Medline] [Order article via Infotrieve]
9.
Poston L, Woolfson RG. Effect of ouabain on
endothelium-dependent relaxation of human
resistance arteries. Hypertension. 1991;17:619-625.
10. Eliades D, Pamnani MB, Swindall BT, Haddy FJ. Effects of bufalin on renal venous outflow urine flow and natriuresis in the anesthetized dog. In: Cox RH, ed. Cellular and Molecular Mechanisms in Hypertension. New York, NY: Plenum Press; 1991:205-210.
11. Pamnani M, Haddy F, Eliades D, Swindall B. A comparison of the acute effects of two putative endogenous Na+,K+-ATPase inhibitors on cardiorenal function in the dog and rat. Hypertension. 1991;17:438-439. Abstract.
12. Yates NA, McDougall JG. Effects of direct renal arterial infusion of bufalin and ouabain in conscious sheep. Br J Pharmacol. 1993;108:627-630.[Medline] [Order article via Infotrieve]
13. Guyton AC, Hall JE, Jackson TE. The basic kidney blood volume-pressure regulatory system: the pressure diuresis and natriuresis phenomena. In: Guyton AC, ed. Arterial Pressure and Hypertension. Philadelphia, Pa: WB Saunders Co; 1980:87-99.
14.
Hall JE, Mizelle HL, Hildebrandt DA, Brands MW.
Abnormal pressure natriuresis: a cause or a consequence of
hypertension? Hypertension. 1990;15:547-559.
15. Hall JE, Granger JP, Hester RL, Montani JP. Mechanisms of sodium balance in hypertension: role of pressure-natriuresis. J Hypertens. 1986;4(suppl 4):S57-S65.
16.
Patel A, Layne S, Watts D, Kirchner KA.
L-Arginine administration normalizes pressure natriuresis
in hypertensive Dahl rats. Hypertension. 1993;22:863-869.
17.
Sample SJG, de Wardener HE. Effect of increased
renal venous pressure on circulatory `auto-regulation' of
isolated dog kidneys. Circ Res. 1959;7:643-648.
18. Brownlee AA, Lee G, Mills IH. Marked inhibition of canine renal Na/K ATPase bifabufodienolide, but weak natriuretic activity in the rat. J Physiol. 1987;390:94P. Abstract.
19. Chen S, Pamnani MB, Dogan A, Swindall BT, Haddy FJ. A comparison of the effects of bufalin and ouabain on rat and guinea pig myocardial Na+, K+-ATPase activity. FASEB J. 1993;7:A548. Abstract.
20. Woolfson RG, Poston L. Effect of ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension. 1991;17:619-625.
21. Woolfson RG, Graves J, LaBella FS, Templeton JF, Poston L. Effect of bufalin and pregnancies on vasoreactivity of human resistance arteries. Biochem Biophys Res Commun.. 1992;186:1-7.
22. Tamaki T, Fukui K, Fujioka S, Iwao H, Okahara T, Abe Y. Effects of ouabain on autoregulation of renal blood flow in dogs. Am J Physiol. 1986;250:F109-F114.
23. Huang BS, Huang X, Harmsen E, Leenen FHH. Chronic central versus peripheral ouabain, blood pressure, and sympathetic activity in rats. Hypertension. 1994;23(pt 2):1087-1090.
This article has been cited by other articles:
![]() |
J. A. Armitage, L. Lakasing, P. D. Taylor, A. A. Balachandran, R. I. Jensen, V. Dekou, N. Ashton, J. R. Nyengaard, and L. Poston Developmental programming of aortic and renal structure in offspring of rats fed fat-rich diets in pregnancy J. Physiol., May 15, 2005; 565(1): 171 - 184. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |